%0 Journal Article
%T Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy
%A Albert Ariza-Sole
%A Alberto Garay
%A Bel谷n Terol
%A Christoph Liebetrau
%A Claudio Moretti
%A Danielle Southern
%A Dimitrios Alexopoulos
%A Dongfeng Zhang
%A Emad Abu Assi
%A Emilio Alfonso
%A Fabrizio D＊Ascenzo
%A Fiorenzo Gaita
%A Francesca Giordana
%A Francesco Colombo
%A Helge Mˋllmann
%A Hiroki Shiomi
%A Ioanna Xanthopoulou
%A Iv芍n Nuˋez-Gil
%A Jing-Yao Fan
%A Jorge Saucedo
%A Jose Paulo Simao Henriques
%A Jos谷 Mar赤a Garc赤a Acuˋa
%A Jos谷 Ram車n Gonz芍lez-Juanatey
%A Kenji Sakata
%A Krzysztof Filipiak
%A Luis CL Correia
%A Mario Iannaccone
%A Masa-aki Kawashiri
%A Masakazu Yamagishi
%A Michal Kowara
%A Neriman Osman
%A Oliver Kalpak
%A Paolo Vadal角
%A Patrizia Noussan
%A Roberto Garbo
%A Sasko Kedev
%A Sergio Raposeiras Roub赤n
%A Shao-Ping Nie
%A Stephen B Wilton
%A Takuya Nakahashi
%A Tetsuma Kawaji
%A Toshiharu Fujii
%A Wouter J Kikkert
%A Xian-tao Song
%A Xiao Wang
%A Yalei Chen
%A Yan Yan
%A Yuji Ikari
%A Zenon Huczek
%J European Heart Journal: Acute Cardiovascular Care
%@ 2048-8734
%D 2018
%R 10.1177/2048872617706501
%X The prevalence and outcome of patients with cancer that experience acute coronary syndrome (ACS) have to be determined. The BleeMACS project is a multicentre observational registry enrolling patients with acute coronary syndrome undergoing percutaneous coronary intervention worldwide in 15 hospitals. The primary endpoint was a composite event of death and re-infarction after one year of follow-up. Bleedings were the secondary endpoint. 15,401 patients were enrolled, 926 (6.4%) in the cancer group and 14,475 (93.6%) in the group of patients without cancer. Patients with cancer were older (70.8㊣10.3 vs. 62.8㊣12.1 years, P<0.001) with more severe comorbidities and presented more frequently with non-ST-segment elevation myocardial infarction compared with patients without cancer. After one year, patients with cancer more often experienced the composite endpoint (15.2% vs. 5.3%, P<0.001) and bleedings (6.5% vs. 3%, P<0.001). At multiple regression analysis the presence of cancer was the strongest independent predictor for the primary endpoint (hazard ratio (HR) 2.1, 1.8每2.5, P<0.001) and bleedings (HR 1.5, 1.1每2.1, P=0.015). Despite patients with cancer generally being undertreated, beta-blockers (relative risk (RR) 0.6, 0.4每0.9, P=0.05), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (RR 0.5, 0.3每0.8, P=0.02), statins (RR 0.3, 0.2每0.5, P<0.001) and dual antiplatelet therapy (RR 0.5, 0.3每0.9, P=0.05) were shown to be protective factors, while proton pump inhibitors (RR 1, 0.6每1.5, P=0.9) were neutral. Cancer has a non-negligible prevalence in patients with acute coronary syndrome undergoing percutaneous coronary intervention, with a major risk of cardiovascular events and bleedings. Moreover, these patients are often undertreated from clinical despite medical therapy seems to be protective. Registration:The BleeMACS project (NCT02466854)
%K Cancer
%K acute coronary syndrome
%K medical therapy
%U https://journals.sagepub.com/doi/full/10.1177/2048872617706501